[1]
|
Huang, K., Yang, T., Xu, J., et al. (2019) Prevalence, Risk Factors, and Management of Asthma in China: A National Cross-Sectional Study. The Lancet, 394, 407-418. https://doi.org/10.1016/S0140-6736(19)31147-X
|
[2]
|
Wang, C., Xu, J., Yang, L., et al. (2018) Prevalence and Risk Factors of Chronic Obstructive Pulmonary Disease in China (The China Pulmonary Health [CPH] Study): A National Cross-Sectional Study. The Lancet, 391, 1706-1717.
https://doi.org/10.1016/S0140-6736(18)30841-9
|
[3]
|
朱琳, 邓婕, 宋洪涛. 抗哮喘药的药物基因组学研究进展[J]. 中国医院药学杂志, 2011, 31(10): 856-859.
|
[4]
|
中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版) [J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205.
https://doi.org/10.3760/cma.j.cn112147-20210109-00031
|
[5]
|
Pinto, C.R., Almeida, N.R., Marques, T.S., et al. (2013) Local Adverse Effects Associated with the Use of Inhaled Corticosteroids in Patients with Moderate or Severe Asthma. Jornal Brasileiro de Pneumologia, 39, 409-417.
https://doi.org/10.1590/S1806-37132013000400003
|
[6]
|
Eric, B., Tim, H., Santiago, Q., et al. (2011) Overall Asthma Control Achieved with Budesonide/Formoterol Maintenance and Reliever Therapy for Patients on Different Treatment Steps. Respiratory Research, 12, Article No. 38.
https://doi.org/10.1186/1465-9921-12-38
|
[7]
|
Mathioudakis, A.G., Amanetopoulou, S.G., Gialmanidis, I.P., et al. (2013) Impact of Long-Term Treatment with Low-Dose Inhaled Corticosteroids on the Bone Mineral Density of Chronic Obstructive Pulmonary Disease Patients: Aggravating or Beneficial? Respirology: Official Journal of the Asian Pacific Society of Respirology, 18, 147-153.
https://doi.org/10.1111/j.1440-1843.2012.02265.x
|
[8]
|
Ozlem, K., Niloufar, F., Esra, B., et al. (2019) Genetic As-sociations of the Response to Inhaled Corticosteroids in Asthma: A Systematic Review. Clinical and Translational Al-lergy, 9, Article No. 2.
https://doi.org/10.1186/s13601-018-0239-2
|
[9]
|
朱丽丽, 张海邻, 李昌崇. 糖皮质激素抗支气管哮喘治疗的药物基因组学研究进展[J]. 国际呼吸杂志, 2017, 37(1): 51-56. https://doi.org/10.3760/cma.j.issn.1673-436X.2017.01.009
|
[10]
|
洪菲萍, 杨一民. 糖皮质激素治疗支气管哮喘的药物基因组学研究进展[J]. 广西医学, 2020, 42(7): 879-882.
|
[11]
|
荀秋芬, 胡成平. 支气管哮喘患者吸入性糖皮质激素疗效与基因多态性研究进展[J]. 国际呼吸杂志, 2016, 36(21): 1670-1673. https://doi.org/10.3760/cma.j.issn.1673-436X.2016.21.016
|
[12]
|
任丹阳, 李云巍, 涂彩霞, 等. ADRB2、GLCCI1、FCER2基因检测在2例难治性哮喘患儿个体化用药中的实践[J]. 中国药房, 2018, 29(5): 659-662. https://doi.org/10.6039/j.issn.1001-0408.2018.05.21
|
[13]
|
张微, 冯琳琳, 平昭. 单核苷酸多态性检测技术研究进展[J]. 生物技术通讯, 2016, 27(6): 879-883.
https://doi.org/10.3969/j.issn.1009-0002.2016.06.030
|
[14]
|
Al-Romaih, K.I., Genovese, G., Al-Mojalli, H., et al. (2011) Genetic Diagnosis in Consanguineous Families with Kidney Disease by Homozygosity Mapping Coupled with Whole-Exome Sequencing. American Journal of Kidney Diseases: The Official Journal of the National Kidney Founda-tion, 58, 186-195.
https://doi.org/10.1053/j.ajkd.2011.01.025
|
[15]
|
Tantisira, K.G., Damask, A., Szefler, S.J., et al. (2012) Ge-nome-Wide Association Identifies the T Gene as a Novel Asthma Pharmacogenetic Locus. American Journal of Respir-atory and Critical Care Medicine, 185, 1286-1291.
https://doi.org/10.1164/rccm.201111-2061OC
|
[16]
|
Palmer, L.J., Silverman, E.S., Weiss, S.T., et al. (2002) Phar-macogenetics of Asthma. American Journal of Respiratory and Critical Care Medicine, 165, 861-866. https://doi.org/10.1164/ajrccm.165.7.2109096
|
[17]
|
Hersh, C.P. (2019) Pharmacogenomics of Chronic Obstructive Pulmonary Disease. Expert Review of Respiratory Medicine, 13, 459-470. https://doi.org/10.1080/17476348.2019.1601559
|
[18]
|
Tantisira, K.G., Lasky-Su, J., Harada, M., et al. (2011) Ge-nomewide Association between GLCCI1 and Response to Glucocorticoid Therapy in Asthma. The New England Journal of Medicine, 365, 1173-1183.
https://doi.org/10.1056/NEJMoa0911353
|
[19]
|
许玉竹. GLCCI1基因多态性与哮喘患者吸入型糖皮质激素的治疗反应性的相关性研究[D]: [硕士学位论文]. 武汉: 华中科技大学, 2014. https://doi.org/10.7666/d.D613343
|
[20]
|
郝珉, 路苓, 李媛媛, 等. GLCCI1和CRHR1基因单核苷酸多态性对支气管哮喘患儿吸入糖皮质激素后肺功能的影响[J]. 当代医学, 2020, 26(35): 120-122. https://doi.org/10.3969/j.issn.1009-4393.2020.35.050
|
[21]
|
KIzuhara, Y., Matsumoto, H., Kanemitsu, Y., et al. (2014) GLCCI1 Variant Accelerates Pulmonary Function Decline in Patients with Asthma Receiving Inhaled Cortico-steroids. Allergy, 69, 668-673. https://doi.org/10.1111/all.12400
|
[22]
|
周淑新. WONCA研究论文摘要汇编——GLCCI1与糖皮质激素哮喘疗法反应的基因组相关[J]. 中国全科医学, 2011, 14(36): 4227.
|
[23]
|
丁颖, 陆敏, 董晓艳, 等. GLCCI1基因多态性对吸入型糖皮质激素治疗儿童哮喘疗效的影响[J]. 中国临床药学杂志, 2017, 26(6): 353-358.
|
[24]
|
Hu, C.P., Xun, Q.F., Li, X.Z., et al. (2016) GLCCI1 Variation Is Associated with Asthma Suscep-tibility and Inhaled Corticosteroid Response in a Chinese Han Population. Archives of Medical Research, 47, 118-125.
https://doi.org/10.1016/j.arcmed.2016.04.005
|
[25]
|
朱双桂, 陈强, 万慕湲, 等. 儿童哮喘吸入性糖皮质激素疗效评价与GLCCI1、FCER2基因多态性的研究[J]. 中国医学创新, 2021, 18(14): 118-123. https://doi.org/10.3969/j.issn.1674-4985.2021.14.029
|
[26]
|
李晓辉, 李奕, 赵二要. GLCCI1基因rs37973位点多态性与支气管哮喘患儿糖皮质激素治疗效果及肺功能的关系[J]. 中国合理用药探索, 2021, 18(10): 51-55. https://doi.org/10.3969/j.issn.2096-3327.2021.10.012
|
[27]
|
邱玉明, 李剑雄, 李慧. 153例汉族哮喘患者GLCCI1基因rs37973位点多态性及吸入糖皮质激素治疗反应[J]. 山东医药, 2016, 56(39): 94-96. https://doi.org/10.3969/j.issn.1002-266X.2016.39.032
|
[28]
|
王星翘, 尹琴, 王天祺, 等. 哮喘患者GLCCI1基因检测指导吸入糖皮质激素的安全性用药效果[J]. 实用临床医药杂志, 2017, 21(1): 34-36. https://doi.org/10.7619/jcmp.201701010
|
[29]
|
李静, 马丽娟, 袁圆, 等. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258. https://doi.org/10.12092/j.issn.1009-2501.2021.11.005
|
[30]
|
Sakornsakolpat, P., Prokopenko, D., Lamontagne, M., et al. (2019) Genetic Landscape of Chronic Obstructive Pulmonary Disease Identifies Heterogeneous Cell-Type and Phenotype Associations. Nature Genetics, 51, 494-505.
|
[31]
|
Hersh, C.P. (2017) Diagnosing alpha-1 Antitrypsin Defi-ciency: The First Step in Precision Medicine. F1000Research, 6, Article No. 2049. https://doi.org/10.12688/f1000research.12399.1
|
[32]
|
Chapman, K.R., Burdon, J.G.W., Piitulainen, E., et al. (2015) Intravenous Augmentation Treatment and Lung Density in Severe α1 Antitrypsin Deficiency (RAPID): A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 386, 360-368. https://doi.org/10.1016/S0140-6736(15)60860-1
|
[33]
|
van den Berge, M., Hiemstra, P.S. and Postma, D.S. (2011) Genetics of Glucocorticoids in Asthma. The New England Journal of Medicine, 365, 2434-2435. https://doi.org/10.1056/NEJMc1112547
|
[34]
|
Lei, Y., Gao, Y.P., Chen, J.K., et al. (2017) GLCCI1 rs37973: A Potential Genetic Predictor of Therapeutic Response to Inhaled Corticosteroids in Chinese Chronic Obstructive Pulmo-nary Disease Patients. Scientific Reports, 10, Article No. 42552. https://doi.org/10.1038/srep42552
|
[35]
|
Singh, D., Bafadhel, M., Brightling, C.E., et al. (2020) Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmo-nary Disease. American Journal of Respiratory and Critical Care Medicine, 202, 660-671.
https://doi.org/10.1164/rccm.201912-2384PP
|
[36]
|
Hastie, A.T., Martinez, F.J., Curtis, J.L., et al. (2017) Associa-tion of Sputum and Blood Eosinophil Concentrations with Clinical Measures of COPD Severity: An Analysis of the SPIROMICS Cohort. The Lancet Respiratory Medicine, 5, 956-967. https://doi.org/10.1016/S2213-2600(17)30432-0
|
[37]
|
Zysman, M., Deslee, G., Caillaud, D., et al. (2017) Rela-tionship between Blood Eosinophils, Clinical Characteristics, and Mortality in Patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease, 20, 1819-1824.
https://doi.org/10.2147/COPD.S129787
|